

## DAFTAR PUSTAKA

1. World Health Organization. Cardiovascular diseases (CVDs): Fact sheet. From: [www.who.int/news-room/factsheets/cardiovascular-diseases-\(cvds\)/](http://www.who.int/news-room/factsheets/cardiovascular-diseases-(cvds)/) Accessed: Jan 2023.
2. Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular Diseases in Europe-epidemiological update 2015. European Heart Journal. 2015;36:2696–2705.
3. Badan Penelitian dan Pengembangan Kesehatan. 2018. Laporan Nasional RISKESDAS 2018. Kementerian Kesehatan RI
4. Sagita VA, Bahtiar A, Andrajati R. Evaluation of a Clinical Pharmacist Intervention on Clinical and Drug-Related Problems Among Coronary Heart Disease
5. Kaufmann CP, Stämpfli D, Hersberger KE, Lampert ML. Determination of risk factors for drug-related problems: A multidisciplinary triangulation process. BMJ Open 2015; 5:e006376. doi: 10.1136/bmjopen-2014-006376.
6. Pharmaceutical Care Network Europe (PCNE). The PCNE Classification V9.1. [https://www.pcne.org/upload/files/417\\_PCNE\\_classification\\_V9-1\\_final.pdf](https://www.pcne.org/upload/files/417_PCNE_classification_V9-1_final.pdf)
7. Garin N, Sole N, Lucas B, Matas L, Moras D, Troyano AR, et al. Drug related problems in clinical practice : a cross - sectional study on their prevalence , risk factors and associated pharmaceutical interventions. Scientific Report. 2021;11(83):9.
8. Deawjaroen K, Sillabuttra J, Poolsup N, Stewart D, Suksomboon N. Characteristics of drug - related problems and pharmacist ' s interventions in hospitalized patients in Thailand : a prospective observational study. Scientific Report. 2022; 12(17107):3-4.
9. Al-Hajje AH, Atoui F, Awada S, Rachidi S, Zein S, Salameh P. Drug-related problems identified by clinical pharmacist's students and pharmacist's interventions. Annales Pharmaceutiques Francaises. 2012;70(3):172
10. Leendertse, A. J. et al. Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study. *Value in Health*. 2011;14(1): 34–40.
11. Hoonhout, L. H. et al. Nature, occurrence and consequences of medication-related adverse events during hospitalization: A retrospective chart review in the Netherlands. *Drug Saf*. 2010;33(10):853–864.
12. Tran AV, Nguyen DT, Tran SK, Vo TH, Nguyen KT, Nguyen PM, Pham ST,

- Duong CX. Coronary Artery Bypass Grafting. IntechOpen (Chapter : Drug-Related Problem in Coronary Artery Disease)
13. Position Paper on the PCNE definition of Medication Review 2016. [http://www.pcne.org/upload/files/149\\_Position\\_Paper\\_on\\_PCNE\\_Medication\\_Review\\_final.pdf](http://www.pcne.org/upload/files/149_Position_Paper_on_PCNE_Medication_Review_final.pdf). Accessed 11 January 2023
  14. Huiskes B, Johan V, Helena *et al.* Effectiveness of medication review on the number of drug- related problems in patients visiting the outpatient cardiology clinic : A randomized controlled trial.Br J Clin Pharmacol. 2019;86:50–61.
  15. Yates L, Valente M, Wardsworth C. Evaluation of Pharmacist Medication Review Service in an Outpatient Heart Failure Clinic. Journal of Pharmacy Practice.2020; 33(6):820-826
  16. Blenkinsopp A, Bond C, Raynor D. Medication Review.Br J Clin Pharmacol.2012;74(4):574
  17. Sim I, Gorman P, Greenes RA, Haynes B, Kaplan B, Lehmann H, Tang PC.Clinical Decision Support Systems for the Practice of Evidence-based Medicine.J Am Med Inform Assoc. 2001;8:527–534.
  18. Damoiseaux-Volman BA, Medlock S, Ploegmakers KJ, *et al.* Priority setting in improving hospital care for older patients using clinical decision support. J Am Med Dir Assoc. 2019;20(8):1045-1047.
  19. Dalton K, O'Brien G, O'Mahony D, Byrne S. Computerised interventions designed to reduce potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-analysis.Age Ageing. 2018;47(5):670-678.
  20. Damoiseaux-Volman BA, van der Velde N, Ruige S, Romijn JA, AbuHanna A, Medlock S. Effect of interventions with a clinical decision support system for hospitalized older patients: a systematic review mapping implementation and design factors. JMIR Med Informatics. 2021;9(7):e28023.
  21. Wells BG, DiPiro JT, Schwinghammer TL, DiPiro C V. Pharmacotherapy Handbook,Tenth Edition. McGraw-Hill Companies. 2017.
  22. nhs.uk. Find out about coronary heart disease (CHD) [internet].2020 [cited 2023 Jan 24]. Available from: <https://www.nhs.uk/conditions/cronary-heart-disease/>
  23. Leon AS, Bronas UG. Pathophysiology of Coronary Heart Disease and Biological Mechanism for the Cardioprotective Effect of Regular Aerobic Exercies. American Journal of Lifestyle Medicine. 2009; 3(5): 379-385.
  24. Zhang X, Sessa WC, Fernandez-Hernando C. Endothelial Trancytosis of

- Lipoprotein in Atherosclerosis. *Frontier in Cardiovascular Medicine*. 2015; 1-6.
25. Willis MS, Howester JW, Stine JR. 2014. Cellular and Molecular Pathobiology of Cardiovascular Disease. London: Elsavier (Chapter 12. Seidman MA, Mitchell RN, Stone JR. Pathophysiology of Atherosclerosis.)
26. Brian K. Alldredge, Robin L. Corelli, Miachael E. Ernst, B. Joseph Guglielmo, Pamala A. Jacobson, Wayne A. Kradjan BRW. Applied Therapeutics The Clinical Use of Drug Tenth Edition. 10th ed. Philadelphia, USA: LIPPINCOTT WILLIAMS & WILKINS, a WOLTERS KLUWER business; 2013:262-262.
27. Frak W, Wosfasinka A, Lisinka W, Mlynarska E, Franczyk B, Rysz J. Pathophysiology of Cardiovascular Disease: New Insight into Molecular Mechanism of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease. *Biomedicine*. 2022;10: 1-17.
28. Liao JK. Linking Endothelial Dysfunction with Endothelial Cell Activation. *J Clin Invest*. 2013;123(5): 540-541
29. Wells BG, DiPiro JT, Schwinghammer TL, DiPiro C V. Pharmacotherapy Handbook,Tenth Edition. McGraw-Hill Companies. 2017: 161-171.
30. Pharmaceutical Care Network Europe (PCNE). The PCNE Classification V9.1.<https://www.pcne.org/upload/files/417> PCNE clasification V9-1 final.pdf
31. Blenkinsopp A, Bond C, Raynor D. K. Medication Review. *Br J Clin Pharmacol*. 2012; 74(4): 573–580
32. Zermansky AG, Petty DR, Raynor DK, Lowe CJ, Freemantle N, Vail A. Clinical medication review by a pharmacist of patients on repeat prescriptions in general practice: a randomised controlled trial. *Health Technol Assess* 2002; 6: 1–86.
33. Vinks T. H. A. M, Egberts T. C. G, de Lange T. M, de Konings F. H. P. Pharmacist-Based Medication Review Reduce Potential Drug-Related Problem in the Elderly. *Drug Aging*. 2009;26(2):123-133.
34. Sim I, Gorman P, Greenes RA, Haynes RB, Kaplan B, Lehmann H, Tang PC. Clinical Desicion Support System for the Practice of Evidance-based Medicine. *J AM Inform Assoc*. 2001;8(6): 528
35. Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An Overview of Clinical Desicion Support System: Benefits, Risks, and Strategies for Succes. *npj Digital Medicine*. 2020;3(17):1-7.
36. Papadopoulos P, Soflano M, Chaudy Y, Adejo W, Connoly TM. A Systemic Review of Technologies and Used in The Development of rule-based Clinical

Medication Support System. Health and Technology. 2022;12:713-727.

37. Medlock S, Wyatt JS, Patel VL, Shortliffe EH, Abu-Hanna A. Modelling Information Flow in Clinical Desicion Support: Key Insight for Enhanching System Efectivness. J AM Inform Assoc. 2016;23:1001-1006.
38. Berners-Lee T. Where the Web was born. CERN website. <https://home.cern/science/computing/birt-web/short-history-web#:text=Where%20the%20Web%20was%20born, and%20institutes%20around%20the%20world.> dipublikasikan pada 12 Maret 2019. diakses pada 2 Maret 2023.
39. Berners-Lee T. History of the Web. Web Foundation website. <https://webfoundation.org/about/vision/history-of-web/>. diakses pada 2 Maret 2023.
40. Dutonde PD, Mamindwar SS, Korvate MS, Bafina S, Shirbhate DD. Website Development Technologies: A Review. IJRASET. 2022; 10(1): 359-366
41. Javapoint. What is HTML?. javapoint website. <https://www.javapoint.com/what-is-html>. diakses pada 2 Maret 2023.
42. Mozilla Developer Network. What is CSS? Mozilla Developer Network website. [https://developer.mozilla.org/en-US/docs/Learn/CSS/First\\_steps/What\\_is\\_CSS](https://developer.mozilla.org/en-US/docs/Learn/CSS/First_steps/What_is_CSS). diakses pada 2 Maret 2023.
43. Mozilla Developer Network. What is JavaScript? Mozilla Developer Network website. [https://developer.mozilla.org/en-US/docs/Learn/JavaScript/First\\_steps/What\\_is\\_JavaScript](https://developer.mozilla.org/en-US/docs/Learn/JavaScript/First_steps/What_is_JavaScript). diakses pada 2 Maret 2023.
44. PHP. What is PHP? PHP website. <https://www.php.net/manual/en/intro-whatis.php>. diakses pada 2 Maret 2023
45. PHP. What can PHP do? PHP website. <https://www.php.net/manual/en/intro-whatcando.php>. diakses pada 2 Maret 2023.
46. MySQL AB. What is MySQL? MySQ website. <https://dev.mysql.com/doc/efman/8.0/what-ismysql.html>. diakses 2 Maret 2023..
47. Schwinghammer TL, Koehler JM. Pharmacotherapy Casebook: A Patient-Focused Approach. Sevent Editions. New York. McGraw-Hill. 2008
48. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). Panduan Praktik Klinis dan Clinical Pathway Penyakit Jantung dan Pembuluh Darah. 2018;1: 4-15.
49. Wells BG, DiPiro JT, Schwinghammer TL, DiPiro C V. Pharmacotherapy Handbook,Tenth Edition. McGraw-Hill Companies. 2017: 18-21.

50. Vital Sign: MedlinePlus Medical Encyclopedia.  
[https://medlineplus.gov/ency/article/002341/htm#:~:text=Blood%20pressure%3A%20between%2090%2f60,%C2%B0F%20\(37%C2%B0C\)](https://medlineplus.gov/ency/article/002341/htm#:~:text=Blood%20pressure%3A%20between%2090%2f60,%C2%B0F%20(37%C2%B0C)). Diakses 30 Juli 2023.
51. What is Data Migration? How Can Companies Benefit from API in Data Migration?. <https://navomi.com/benefits-of-api-in-data-migration/> Diakses pada 25 Agustus 2023.
52. Wright A, Sittig DF. A Framework and Model for Evaluating Clinical Decision Support Architectures. *Journal of Biomedical Informatics* 41 (2008) 982–990
53. Juliois, SA. Sample Size of 12 per Group rule of Thumb for a Pilot Study, *Pharmaceutical Statistics*. 2005; 4(4): 287-291.
54. Damoiseaux-Volman BA, Medlock S, Van der Mullen DM, de Boer J, Van der Velde N.. Clinical Validation of Clinical Decision Support System for Medication Review : A Scoping Review. *Br J Pharmacol.* 2022;8:2035-2051.

